- Home
- QD vs CELC Comparison
QD vs CELC Comparison
Compare QD & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QD
- CELC
- Stock Information
- Founded
- QD 2014
- CELC 2011
- Country
- QD China
- CELC United States
- Employees
- QD N/A
- CELC N/A
- Industry
- QD Finance: Consumer Services
- CELC Medical Specialities
- Sector
- QD Finance
- CELC Health Care
- Exchange
- QD Nasdaq
- CELC Nasdaq
- Market Cap
- QD 433.7M
- CELC 440.0M
- IPO Year
- QD 2017
- CELC 2017
- Fundamental
- Price
- QD $3.33
- CELC $13.63
- Analyst Decision
- QD
- CELC Strong Buy
- Analyst Count
- QD 0
- CELC 6
- Target Price
- QD N/A
- CELC $30.67
- AVG Volume (30 Days)
- QD 614.1K
- CELC 206.7K
- Earning Date
- QD 09-05-2025
- CELC 08-13-2025
- Dividend Yield
- QD N/A
- CELC N/A
- EPS Growth
- QD N/A
- CELC N/A
- EPS
- QD 0.24
- CELC N/A
- Revenue
- QD $25,682,957.00
- CELC N/A
- Revenue This Year
- QD N/A
- CELC N/A
- Revenue Next Year
- QD N/A
- CELC N/A
- P/E Ratio
- QD $14.14
- CELC N/A
- Revenue Growth
- QD 16.24
- CELC N/A
- 52 Week Low
- QD $1.64
- CELC $7.58
- 52 Week High
- QD $3.50
- CELC $19.77
- Technical
- Relative Strength Index (RSI)
- QD 70.43
- CELC 62.38
- Support Level
- QD $3.20
- CELC $12.48
- Resistance Level
- QD $3.50
- CELC $14.19
- Average True Range (ATR)
- QD 0.14
- CELC 0.75
- MACD
- QD 0.04
- CELC 0.07
- Stochastic Oscillator
- QD 79.67
- CELC 80.73
About QD Qudian Inc. each representing one
Qudian Inc is a consumer-oriented technology company engaged in the operation of online platforms to provide small consumer credit products in the People's Republic of China. It aims to empower financial institutions with its technological capabilities, help them improve marketing and operating efficiency, and enable financial institutions to efficiently connect their diversified financial products with scene traffic across the entire network It derives a majority of its revenue from the People's Republic of China.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.